Almeida J G, Christian M, Chacko C J
Int J Lepr Other Mycobact Dis. 1983 Sep;51(3):378-8.
At the Schieffelin Leprosy Research and Training Centre, Karagiri, India, 148 lepromatous (LL) and borderline lepromatous (BL) leprosy patients registered for treatment in the years 1971 to 1973 were found to respond as well to dapsone (DDS) monotherapy as 391 LL and BL patients registered in 1964 to 1966, as indicated by clearance of Mycobacterium leprae from skin smears during the initial seven years of therapy in each patient. Apparently, the efficacy of DDS monotherapy has not been progressively diminishing since the introduction of DDS monotherapy into the area.
在印度卡拉吉里的谢弗林麻风病研究与培训中心，研究发现，1971年至1973年登记接受治疗的148例瘤型（LL）和界线类偏瘤型（BL）麻风病患者，对氨苯砜（DDS）单一疗法的反应与1964年至1966年登记的391例LL和BL患者相同，这一点从每位患者治疗最初七年期间皮肤涂片上麻风分枝杆菌的清除情况可以看出。显然，自该地区引入DDS单一疗法以来，DDS单一疗法的疗效并未逐渐降低。
